Zambia has reached an important milestone in its national HIV prevention response following the arrival of its first shipment of lenacapavir, an innovative HIV prevention medicine administered twice a year. The shipment arrived yesterday at the University Teaching Hospital (UTH) in Lusaka, where Permanent Secretary for Donor Coordination at the Ministry of Health, Dr George Sinyangwe, represented the Zambian Government. The introduction of lenacapavir gives the country an additional option for preventing HIV infection alongside existing interventions under the national HIV response. The development is particularly significant because the medicine offers a new prevention option for pregnant and breastfeeding women. It also supports Zambia’s broader efforts to strengthen HIV prevention and accelerate progress towards eliminating mother to child transmission of HIV.
Lenacapavir is being introduced as part of Zambia’s continued efforts to expand access to effective HIV prevention services. Unlike prevention options that require more frequent administration, lenacapavir is administered twice a year, offering a longer-acting approach to HIV prevention. This can provide an additional choice for people who may face challenges with prevention methods that require frequent use or regular adherence. The availability of another prevention option also allows healthcare programmes to respond to the different needs and circumstances of people who require HIV prevention services. Its arrival therefore represents an important development in Zambia’s strategy to broaden and strengthen the tools available to communities as the country works to reduce new HIV infections.
The introduction of lenacapavir is also significant for pregnant and breastfeeding women, who require effective HIV prevention and specialised healthcare support. Preventing HIV infection among women during pregnancy and breastfeeding remains an important part of efforts to eliminate mother to child transmission of HIV. By providing another prevention option, lenacapavir has the potential to complement services already available through Zambia’s national HIV programme. Strengthening prevention among women can help protect mothers while also contributing to efforts to reduce the risk of HIV transmission to children. The arrival of the medicine therefore connects Zambia’s HIV prevention goals with its broader maternal and child health priorities.
The milestone also strengthens Zambia’s national Pre-Exposure Prophylaxis programme, commonly known as PrEP. PrEP forms an important part of combination HIV prevention because it gives people at risk of HIV an additional tool to reduce their chances of acquiring the virus. The introduction of lenacapavir expands the range of prevention approaches that can be considered within the national programme. Zambian health experts are providing technical support as the country introduces the new medicine, highlighting the importance of local expertise in implementing innovative health interventions. Building local technical capacity can help ensure that new prevention technologies become integrated effectively into the country’s healthcare system.
The arrival of Zambia’s first lenacapavir shipment also highlights the importance of international cooperation in strengthening the country’s health system. The medicine arrived from the United States of America, demonstrating continued cooperation between Zambia and the United States in supporting HIV prevention and other health priorities. International partnerships can provide access to new medical technologies while also supporting technical expertise, programme implementation and health system strengthening. For Zambia, such cooperation can complement domestic efforts to improve prevention services and address the ongoing HIV burden. The shipment therefore represents not only the arrival of a new medicine but also an example of how international partnerships can support national health priorities.
The milestone was marked at the University Teaching Hospital in Lusaka, one of Zambia’s key healthcare institutions. The programme included a tour of the UTH Women and Newborn Hospital Maternal and Child Health Wing, bringing particular attention to the connection between HIV prevention and maternal and newborn healthcare. Integrating HIV prevention into services that support women and children is important for reaching people at different stages of pregnancy, childbirth and breastfeeding. It can also help healthcare providers identify prevention needs and connect patients with appropriate services. The activities at UTH therefore provided an important setting for highlighting how new HIV prevention technologies can contribute to broader maternal and child health objectives.
The introduction of lenacapavir also demonstrates Zambia’s willingness to embrace medical innovation as part of its response to public health challenges. HIV prevention has evolved significantly over the years, with new medicines and delivery approaches creating more options for people who want to protect themselves from infection. However, introducing an innovative medicine requires more than simply receiving shipments, as health workers need appropriate technical knowledge and programmes need systems for delivery, monitoring and follow-up. Zambia’s use of local health expertise in supporting the introduction is therefore an important part of the process. Combining innovation with local knowledge can help strengthen implementation and ensure that new interventions contribute meaningfully to the national HIV response.
The twice-yearly administration of lenacapavir could also have practical implications for HIV prevention services. Prevention methods that require less frequent administration may offer greater convenience for eligible individuals while potentially reducing some of the challenges associated with maintaining frequent medication schedules. At the same time, successful implementation will depend on ensuring that people receive accurate information, appropriate clinical guidance and reliable access to follow-up services. Healthcare workers will play an important role in explaining how the medicine is used and helping individuals make informed decisions about HIV prevention. These considerations will be important as Zambia incorporates lenacapavir into its existing prevention programme.
Zambia’s first shipment of lenacapavir comes at a time when the country continues to pursue stronger HIV prevention outcomes and progress towards eliminating mother to child transmission. The medicine does not replace existing HIV prevention measures but adds another option to the national response. Its value will depend on effective integration with other prevention services, continued technical support and the ability of the health system to reach people who can benefit from it. Sustained investment in healthcare workers, community awareness and prevention services will remain important as Zambia expands access to innovative HIV interventions. The country’s approach shows the importance of combining new medical technologies with established public health programmes.
The arrival of lenacapavir at UTH marks a significant step in Zambia’s ongoing HIV prevention efforts and reflects the country’s commitment to using innovation, partnerships and local expertise to improve health outcomes. The twice-yearly HIV prevention medicine provides an additional option within the national PrEP programme while offering particular potential for pregnant and breastfeeding women. Its introduction also reinforces the importance of cooperation between Zambia and the United States in supporting the country’s health priorities. As implementation progresses, effective healthcare delivery, technical expertise and continued investment will be essential to achieving the full potential of the new intervention. Zambia’s first lenacapavir shipment therefore represents an important development in the national HIV response and another step towards stronger HIV prevention and the goal of eliminating mother to child transmission of HIV.